Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Metronome Therapeutics
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
capable of understanding study requirements and able to provide Informed Consent
diagnosed with a non-hematologic malignancy for which there are no currently accepted therapies
life expectancy at least 3 months
agreement to use medically acceptable contraception throughout the study
willing and able to comply with the protocol requirements
You may not be if
currently receiving systemic treatment for malignancy
not yet recovered from the toxicity of prior therapies
platelet count \< 100,000 cells/mm3 within 7 days prior to study entry
ANC \< 1500 cells/mm3 within 7 days prior to study entry
hemoglobin \< 8.5 g/dL within 7 days prior to study entry
AST and/or ALT \> 2.5 X ULN within 7 days prior to study entry
total bilirubin \> 1.5 X ULN within 7 days prior to study entry
creatinine clearance \< 60 mL/min (Cockroft-Gault formula) within 7 days prior to study entry
receipt of any investigational therapy within 3 weeks prior to study entry
known history of HIV, HBV, and/or HCV infection
clinically relevant active infection or serious co-morbid medical condition at study entry
major surgery within 4 weeks prior to study entry
other malignancy within 3 year prior to study entry
pregnant or breast-feeding
presence of a concomitant disease or condition which, in the opinion of the Investigator, could interfere with the conduct of the study or could put the subject at unacceptable risk
Clareo Health | Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies
